Curevo Vaccine, a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly effective vaccines, announced Guy De La Rosa has joined the company as its new chief medical officer.
“The Curevo team is excited to welcome Dr. De La Rosa to the company,” said George Simeon, Curevo’s CEO. “Guy, with his 20-plus years of experience directing clinical trials in the infectious disease space, will immediately bring a positive impact to our CRV-101 vaccine programs against shingles and chickenpox.”
